Merck & Co., Inc. (NYSE:MRK) Given Consensus Rating of “Moderate Buy” by Analysts

Merck & Co., Inc. (NYSE:MRK) has received an average recommendation of “Moderate Buy” from the twenty research firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $134.50.

MRK has been the subject of a number of recent research reports. Bank of America increased their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. CICC Research started coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. UBS Group increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Morgan Stanley raised their price target on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Finally, Scotiabank boosted their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, June 30th.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target to $150 from $140 and maintained an “overweight” rating, implying roughly 15% upside from the referenced price. The increase reflects continued confidence in Merck’s outlook. Barclays raises Merck price target
• Positive Sentiment: KEYTRUDA met its primary progression-free-survival endpoint in a Phase 3 trial for advanced or recurrent endometrial cancer, outperforming platinum-based chemotherapy. Merck said the result could support future regulatory filings and strengthen its oncology pipeline. Merck KEYTRUDA endometrial cancer trial
• Positive Sentiment: Merck announced its fourth-quarter 2026 dividend, reinforcing the stock’s appeal to income-oriented investors and signaling continued capital-return support. The provided announcement did not include the dividend amount or payment details. Merck fourth-quarter dividend announcement
• Neutral Sentiment: Wells Fargo reiterated its Buy rating, while broader brokerage coverage places Merck at a “Moderate Buy” consensus, indicating generally favorable but not universally bullish sentiment. Wells Fargo maintains Merck Buy rating
• Negative Sentiment: Analysts expect Merck’s second-quarter earnings to decline, and a Zacks preview says the company lacks the typical signals associated with a likely earnings beat. This raises near-term execution risk ahead of the earnings report. Merck second-quarter earnings preview

Institutional Trading of Merck & Co., Inc.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Somerset Trust Co lifted its stake in Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after purchasing an additional 81 shares during the last quarter. Stonebridge Financial Group LLC increased its position in Merck & Co., Inc. by 0.9% during the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after buying an additional 81 shares during the last quarter. Stronghold Wealth Management L.L.C. increased its position in Merck & Co., Inc. by 2.6% during the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock worth $416,000 after buying an additional 82 shares during the last quarter. Lederer & Associates Investment Counsel CA raised its stake in Merck & Co., Inc. by 0.9% in the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock valued at $1,234,000 after buying an additional 84 shares during the period. Finally, Pine Haven Investment Counsel Inc raised its stake in Merck & Co., Inc. by 0.6% in the second quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock valued at $1,834,000 after buying an additional 86 shares during the period. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $130.45 on Thursday. Merck & Co., Inc. has a 12 month low of $77.53 and a 12 month high of $135.05. The company’s fifty day simple moving average is $122.73 and its 200-day simple moving average is $118.24. The firm has a market cap of $322.18 billion, a PE ratio of 36.75, a P/E/G ratio of 5.23 and a beta of 0.19. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the business earned $2.22 EPS. The company’s revenue was up 4.9% compared to the same quarter last year. Equities research analysts expect that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.